Overview

Corporate ProfileNantHealth is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. In addition, NantHealth’s adaptive learning system, CLINICS, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time.
Stock Quote NH (Common Stock) $3.07 - 0.02 (0.65%)
ExchangeNASDAQ GS
Volume74,781
Today's Open$3.09
Previous Close$3.09
Data as of 05/26/17 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NH.O.  Currently trading at $3.07 with a 52 week high of $21.00 and a 52 week low of $2.94.
Recent News

May 23, 2017

NantHealth Names Ronald A. Louks as Chief Operating Officer

CULVER CITY, Calif.--(BUSINESS WIRE)--May 23, 2017-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced the appointment of Ronald A. Louks as its Chief Operating Officer. “Ron brings senior level leadership and excellent experience, gained at some of the most highly regarded and well recognized companies in the world, including Blackberry, HTC and Sony Ericsson,” said Patrick ...

Read More >

May 10, 2017

NantHealth Appoints Dr. Sandeep Reddy as Chief Medical Officer

Company adds established oncology expert to leadership team CULVER CITY, Calif.--(BUSINESS WIRE)--May 10, 2017-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, announced today the appointment of Sandeep (Bobby) Reddy, MD, as Chief Medical Officer. In his new position, Dr. Reddy will be responsible for overseeing education, outreach, clinical development programs, and clinical trials for GP...

Read More >

May 10, 2017

NantHealth Reports 16% Increase in 2017 First Quarter Total Net Revenue; SaaS Revenue Rose 11% and GPS Adoption Continues to Climb

GPS Adoption: GPS Cancer Test to Be Complementary Diagnostic for FDA Authorized Nant Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer 365 GPS Commercial Tests Ordered in Q1, Up from 326 in Q4 ‘16 266 GPS Commercial Tests Delivered in Q1, Up from 233 in Q4 ‘16 ...

Read More >

Upcoming Events
DateTitle
06/06/17
through
06/09/17
NantHealth at Jefferies 2017 Global Healthcare Conference
Location New York, NY